skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Informa pharma logo

Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC

This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Pharma Intelligence Logo
Search Icon Pharma Report StoreRecommendationsProduct loginProductLogin
Global Search Configuration

Datamonitor Healthcare has identified the following key highlights from the 50th American Society of Clinical Oncology (ASCO) Annual Meeting, which was held between 30 May and 3 June 2014:

 

  • Results from early-phase clinical trials of AstraZeneca’s AZD9291 and Clovis Oncology’s CO-1686 demonstrate strong efficacy of both drugs in relapsed/refractory non-small cell lung cancer (NSCLC) patients with T790M mutations.

 

  • Programmed death 1-targeted immunotherapies were a key highlight of ASCO 2014.

 

  • Imbruvica’s (ibrutinib; Pharmacyclics/Janssen Biotech) Phase III RESONATE results confirm its strong efficacy as a single agent for the treatment of chronic lymphocytic leukemia (CLL).

 

  • Phase II data demonstrate Amgen’s novel antibody therapy blinatumomab is highly effective as a treatment for Philadelphia chromosome (Ph)-negative relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL).

 

  • Results from the Phase II ROMULUS trial showed that when combined with Rituxan (rituximab; Roche), Roche’s investigational antibody-drug conjugates polatuzumab vedotin (PoV) and pinatuzumab vedotin (PiV) are clinically active and well tolerated in relapsed/refractory follicular lymphoma (FL) and relapsed/refractory diffuse large B-cell lymphoma (DLBCL) patients.

Highlights from the ASCO 2014 Conference review include:

Results from early-phase clinical trials of AstraZeneca’s AZD9291

Imbruvica's (Ibrutinib; Pharmacyclics/Janssen Biotech) Phase III RESONATE results

Results from the Phase II ROMULUS trial

 

Post-ASCO-2014
Download whitepaper

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Request a free demo

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888 670 8900
  • US Toll           : +1 908 547 2200
  • UK & Europe : +44 (20) 337 73737
  • Australia        : +61 2 8705 6907
  • Japan              : +81 3 6273 4260

Or please submit your inquiry via the form so that we can provide you the best possible customer service.
General enquiry

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now:

Shop now